drugset / Trial / NCT04528082

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

NCT04528082

Phase 3 Recruiting 60 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.

Timeline

Start
2021-09-09
Primary completion
2030-02-07
Completion
2030-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule Oral

Indications